BlackRock Institutional Trust’s Myriad Genetics MYGN Stock Holding History

BlackRock Institutional Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$29.3M	Sell	1,755,099 -79,760	-4%	-$1.44M	﹤0.01%	1687
2016 Q3	$37.8M	Buy	1,834,859 +1,568	+0.1%	+$39.8K	0.01%	1463
2016 Q2	$56.1M	Sell	1,833,291 -32,139	-2%	-$1.12M	0.01%	1167
2016 Q1	$69.8M	Buy	1,865,430 +121,266	+7%	+$4.57M	0.01%	1033
2015 Q4	$75.3M	Buy	1,744,164 +70,504	+4%	+$2.98M	0.01%	1000
2015 Q3	$62.7M	Sell	1,673,660 -57,307	-3%	-$2.03M	0.01%	1106
2015 Q2	$58.8M	Sell	1,730,967 -142,168	-8%	-$4.83M	0.01%	1208
2015 Q1	$66.3M	Sell	1,873,135 -38,974	-2%	-$1.39M	0.01%	1156
2014 Q4	$65.1M	Buy	1,912,109 +48,254	+3%	+$1.71M	0.01%	1122
2014 Q3	$71.9M	Sell	1,863,855 -8,577	-0.5%	-$320K	0.01%	1038
2014 Q2	$72.9M	Sell	1,872,432 -14,529	-0.8%	-$541K	0.01%	1071
2014 Q1	$64.5M	Sell	1,886,961 -280,729	-13%	-$8.7M	0.01%	1126
2013 Q4	$45.5M	Buy	2,167,690 +172,634	+9%	+$4.37M	0.01%	1328
2013 Q3	$46.9M	Sell	1,995,056 -95,165	-5%	-$2.7M	0.01%	1244
2013 Q2	$56.2M	Buy	+2,090,221	New	+$60.6M	0.01%	1076

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock Institutional Trust's MYGN Position: Q4 2016 in Review

BlackRock Institutional Trust reduced its Myriad Genetics (MYGN) stake by 4.3% in Q4 2016, selling an estimated $1.44M and leaving 1,755,099 shares worth $29.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1687.

BlackRock Institutional Trust first reported a position in MYGN in Q2 2013 and has held it in 15 quarters since. The position peaked at $75.3M in Q4 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

BlackRock Institutional Trust held 1,755,099 shares of Myriad Genetics worth $29.3M as of Q4 2016.
BlackRock Institutional Trust sold 79,760 Myriad Genetics shares in Q4 2016, an estimated $1.44M.
Myriad Genetics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1687 holding.
BlackRock Institutional Trust first reported a position in Myriad Genetics in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Myriad Genetics position peaked at $75.3M in Q4 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.